Bristol-Myers Squibb Pharma Company

Bristol-Myers Squibb Compnay

Other

Lorin Andrew Thompson

Richard Eric Olson

Thomas P Maduskuie, Jr

Hong Liu

Dietmar A Seiffert

Robert Zaczek

Amy Han

Andrew J Tebben

Wei Deng

Nenghui Wang

This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&#x3b2;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &#x3b2;-amyloid production such as Alzheimer's disease and Down's Syndrome.

Succinoylamino lactams as inhibitors of a-&#x3b2; protein production

This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&#x3b2;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &#x3b2;-amyloid production such as Alzheimer's disease and Down's Syndrome.

Hydroxyalkanoylaminolactams and related structures as inhibitors of a&#x3b2; protein production

Hydroxyalkanoylaminolactams and related structures as inhibitors of A&#x3b2; protein production

Succinoylamino lactams as inhibitors of A&#x3b2; protein production

This invention relates to a novel method of screening for inhibitors of beta-amyloid production, and thereby identifying such inhibitors as therapeutics for neurological and other disorders involving APP processing and beta-amyloid production. This invention also relates to identifying macromolecules involved in APP processing and beta-amyloid production. Furthermore, inhibitors identified by the screening method of the present invention are useful in the treatment of neurological disorders, such as Alzheimer's disease, which involve elevated levels of A&#x3b2; peptides.

Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging

Succinoylamino lactams as inhibitors of A-&#x3b2; protein production

This invention relates to novel compounds of the class of succinoyl lactams, such as diazepinee of Formula (Id),or a pharmaceutically acceptable salt thereof, as described above, having drug and bio-affecting properties. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&#x3b2;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of Alzheimer's disease.

Benzo-1,4-diazepin-2-ones as inhibitors of A&#x3b2; protein production

This invention relates to novel lactams having the formula (I):to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&#x3b2;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &#x3b2;-amyloid production such as Alzheimer's disease and Down's Syndrome.

A method of using radiolabelled and/or radiopharmaceutical small molecule inhibitors of beta-amyloid peptide production for the diagnosis of neurological and other disorders involving APP processing and beta-amyloid production. Radiolabelled small molecule inhibitors identified by the methods of the present invention would be useful in the diagnosis of neurological disorders, such as Alzheimer's disease, which involve elevated levels of A&#x3b2; peptides.

This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

Succinoylamino lactams as inhibitors of a&bgr; protein

This invention relates to a novel method of screening for inhibitors of beta-amyloid production, and thereby identifying such inhibitors as therapeutics for neurological and other disorders involving APP processing and beta-amyloid production. This invention also relates to identifying macromolecules involved in APP processing and beta-amyloid production. Furthermore, inhibitors identified by the screening method of the present invention are useful in the treatment of neurological disorders, such as Alzheimer's disease, which involve elevated levels of A&bgr; peptides.

This invention relates to novel carbocycles and heterocycles having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

Growing community of inventors

Wilmington, DE, United States of America

Lorin Andrew Thompson